The US Food and Drug Administration (FDA) has announced recommendations for supporting gene therapies aimed at tacking haemophilia, retinal disorders and rare diseases. A call for cheaper meds​ It said the suggestions reflecting increasing work in gene therapy could be used by sponsors to speed a drug’s official FDA approval. The FDA has already approved the Kymriah therapy from Novartis, Gilead Sciences’ Yescarta and the Luxturna therapy from Spark Therapeutics and Kymriah has now won a second approval. “Gene therapy is an exciting new approach that can help patients with many different types of diseases,” says Dr David Sinclair, director of the National Institute on Blood Disorders (NIHD) at NIH.
The US Food and Drug Administration (FDA) has announced recommendations for supporting gene therapies aimed at tacking haemophilia, retinal disorders and rare diseases. It said the suggestions reflecting increasing work in gene therapy could be used by sponsors to speed a drug’s official FDA approval. The FDA has already approved the Kymriah therapy from Novartis, Gilead Sciences’ Yescarta and the Luxturna therapy from Spark Therapeutics and Kymriah has now won a second approval. “Gene therapy is an exciting new approach that can help patients with many different types of diseases,” says Dr David Sinclair, director of the National Institute on Blood Disorders (NIHD) at NIH.